Role of GPR110 on tumorigenesis and metastasis in HER2+breast cancer in the context of anti-HER2 drug resistance

被引：0
|
作者：
Sahay, Debashish
Bhat, Raksha
Rimawi, Motthafar
Osborne, C. Kent
Schiff, Rachel
Trivedi, Meghana V.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
319
引用
收藏
页数：3
相关论文
共 50 条
  • [1] GPR110 overexpression increases tumorigenic potential of HER2+breast cancer cells
    Trivedi, M. V.
    Bhat, R.
    Yadav, V.
    Yadav, P.
    Ai-Rawi, A.
    Christiny, P.
    Nanda, S.
    Giuliano, M.
    Creighton, C.
    Osborne, C. K.
    Narkar, V. A.
    Schiff, R.
    CANCER RESEARCH, 2013, 73
  • [2] Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer
    Gagliato, Debora de Melo
    Fontes Jardim, Denis Leonardo
    Pereira Marchesi, Mario Sergio
    Hortobagyi, Gabriel N.
    ONCOTARGET, 2016, 7 (39) : 64431 - 64446
  • [3] GPCRs profiling and identification of GPR110 as a potential new target in HER2+breast cancer
    Bhat, Raksha R.
    Yadav, Puja
    Sahay, Debashish
    Bhargava, Dharmendra K.
    Creighton, Chad J.
    Yazdanfard, Sahar
    Al-rawi, Ahmed
    Yadav, Vikas
    Qin, Lanfang
    Nanda, Sarmistha
    Sethunath, Vidyalakshmi
    Fu, Xiaoyong
    De Angelis, Carmine
    Narkar, Vihang A.
    Osborne, C. Kent
    Schiff, Rachel
    Trivedi, Meghana V.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 279 - 292
  • [4] The role of GPR110 in tumorigenicity, tumor cell dissemination, and cell cycle regulation in HER2+breast cancer
    Bhat, Raksha
    Qin, Lanfang
    De Angelis, Carmine
    Vasaikar, Suhas
    Thangavel, Hariprasad
    AbdulKareem, Noor
    Zhang, Bing
    Schiff, Rachel
    Trivedi, Meghana V.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+breast cancer
    Hu, Huizhong
    Simon, Lukas
    Qin, Lanfang
    Nardone, Agostina
    Shaw, Chad
    Chamness, Gary
    Heiser, Laura
    Wang, Nicholas
    Gray, Joe W.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [6] Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy
    Sethunath, Vidyalakshmi
    Hu, Huizhong
    DeAngelis, Carmine
    Veeraraghavan, Jamunarani
    Qin, Lanfang
    Shea, Martin
    Mitchell, Tamika
    Nanda, Sarmistha
    Pereira, Resel
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, Kent C.
    Schiff, Rachel
    CANCER RESEARCH, 2019, 79 (13)
  • [7] circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+breast cancer patients
    Ling, Yun
    Liang Gehao
    Liu, Zihao
    Tian, Zhenluan
    Zhong, Wenjing
    Lin, Wanyi
    Chang, Gong
    CANCER RESEARCH, 2020, 80 (04)
  • [8] Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer
    Liu, Yunhua
    He, Xiaoming
    Lu, Xiongbin
    Zhang, Xinna
    CANCER RESEARCH, 2019, 79 (13)
  • [9] Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+breast cancer
    Liu, Yunhua
    Xu, Jiangsheng
    Choi, Hyun Ho
    Han, Cecil
    Fang, Yuanzhang
    Li, Yujing
    Van der Jeught, Kevin
    Xu, Hanchen
    Zhang, Lu
    Frieden, Michael
    Wang, Lifei
    Eyvani, Haniyeh
    Sun, Yifan
    Zhao, Gang
    Zhang, Yuntian
    Liu, Sheng
    Wan, Jun
    Huang, Cheng
    Ji, Guang
    Lu, Xiongbin
    He, Xiaoming
    Zhang, Xinna
    NATURE COMMUNICATIONS, 2018, 9
  • [10] Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+breast cancer (BC): A network meta-analysis (NMA).
    Pelizzari, Giacomo
    Gerratana, Lorenzo
    Basile, Debora
    Bartoletti, Michele
    Lisanti, Camilla
    Garattini, Silvio Ken
    Bortot, Lucia
    Corvaja, Carla
    Buriolla, Silvia
    Curtolo, Gianluca
    Garutti, Mattia
    Di Nardo, Paola
    Torrisi, Elena
    Da Ros, Lucia
    Freschi, Andrea
    Saracchini, Silvana
    Bolzonello, Silvia
    Miolo, Gianmaria
    Spazzapan, Simon
    Puglisi, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345